| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-507
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2800-107 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-1282
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-85
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-13
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-85
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-12 |
| filingDate |
2020-08-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2022-02-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2022-02-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-111909265-B |
| titleOfInvention |
Humanized antibody combined with tetanus toxin heavy chain C-terminal domain and application |
| abstract |
The invention discloses a humanized antibody combined with a tetanus toxin heavy chain C-terminal structural domain, which has a unique CDR region and has affinity with antigen reaching 0.397 nM. The antibody can effectively neutralize tetanus toxin and can completely protect mice attacked by the tetanus toxin. The antibody provided by the invention has a unique action site, is different from the action site of the anti-tetanus toxin monoclonal antibody in the prior art, and suggests that the antibody has the potential of composing cocktail combination therapy with other neutralizing antibodies. |
| priorityDate |
2020-08-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |